Emergex is pioneering a new approach to vaccine development, in order to address some of the world’s most acute health threats such as Zika, Ebola, pandemic flu and antibiotic-resistant bacteria.

In these White papers we describe the challenges of developing an effective vaccine for Zika and Influenza (flu) and explain why we believe our approach addresses many of the issues: